A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Authors
Keywords
-
Journal
CNS DRUGS
Volume 32, Issue 11, Pages 1053-1067
Publisher
Springer Nature America, Inc
Online
2018-10-30
DOI
10.1007/s40263-018-0578-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Elizabeth A Thiele et al. LANCET
- Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
- (2018) Orrin Devinsky et al. NEUROLOGY
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
- (2018) Orrin Devinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interactions between cannabidiol and commonly used antiepileptic drugs
- (2017) Tyler E. Gaston et al. EPILEPSIA
- The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate
- (2017) Barry E. Gidal et al. EPILEPSY RESEARCH
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
- (2017) Orrin Devinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cannabinoids and Cytochrome P450 Interactions
- (2016) Ondřej Zendulka et al. CURRENT DRUG METABOLISM
- Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex
- (2016) Evan J. Hess et al. EPILEPSIA
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
- (2016) Orrin Devinsky et al. LANCET NEUROLOGY
- Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
- (2015) John M McPartland et al. BRITISH JOURNAL OF PHARMACOLOGY
- Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy
- (2015) Alexandra L. Geffrey et al. EPILEPSIA
- Absorption-Enhancing Effects of Bile Salts
- (2015) Eskandar Moghimipour et al. MOLECULES
- Molecular Targets of Cannabidiol in Neurological Disorders
- (2015) Clementino Ibeas Bih et al. Neurotherapeutics
- Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review
- (2013) Stephen M. Stout et al. DRUG METABOLISM REVIEWS
- Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses
- (2013) S. Sylantyev et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes
- (2011) Rongrong Jiang et al. LIFE SCIENCES
- Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55
- (2011) Christopher M. Henstridge et al. MOLECULAR ENDOCRINOLOGY
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- (2009) A. Mazur et al. DRUG METABOLISM AND DISPOSITION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now